IceCure Medical (NASDAQ:ICCM) Given Buy Rating at HC Wainwright

IceCure Medical (NASDAQ:ICCM)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report issued on Tuesday, Benzinga reports. They currently have a $3.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 132.56% from the stock’s current price.

Separately, Alliance Global Partners raised their target price on shares of IceCure Medical from $1.90 to $2.90 and gave the company a “buy” rating in a research note on Wednesday, March 20th.

IceCure Medical Trading Down 0.8 %

NASDAQ ICCM opened at $1.29 on Tuesday. IceCure Medical has a 12 month low of $0.52 and a 12 month high of $1.57. The company has a current ratio of 3.66, a quick ratio of 3.08 and a debt-to-equity ratio of 0.03. The stock has a 50 day moving average of $1.28 and a 200-day moving average of $1.11. The company has a market cap of $58.85 million, a PE ratio of -3.91 and a beta of 0.73.

IceCure Medical (NASDAQ:ICCM) last posted its quarterly earnings results on Wednesday, April 3rd. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01. The firm had revenue of $1.26 million for the quarter. IceCure Medical had a negative net margin of 453.76% and a negative return on equity of 86.96%. During the same period last year, the company posted ($0.11) earnings per share. On average, equities research analysts anticipate that IceCure Medical will post -0.28 EPS for the current fiscal year.

Institutional Investors Weigh In On IceCure Medical

Several hedge funds have recently added to or reduced their stakes in ICCM. Bank of America Corp DE increased its holdings in shares of IceCure Medical by 57.2% in the fourth quarter. Bank of America Corp DE now owns 55,388 shares of the company’s stock valued at $86,000 after purchasing an additional 20,159 shares during the last quarter. Boothbay Fund Management LLC lifted its stake in shares of IceCure Medical by 100.0% during the 4th quarter. Boothbay Fund Management LLC now owns 40,000 shares of the company’s stock worth $62,000 after buying an additional 20,000 shares during the last quarter. UBS Group AG boosted its holdings in shares of IceCure Medical by 1,302.3% during the 4th quarter. UBS Group AG now owns 28,986 shares of the company’s stock worth $45,000 after buying an additional 26,919 shares during the period. Finally, JPMorgan Chase & Co. bought a new stake in shares of IceCure Medical during the 2nd quarter worth about $78,000. Institutional investors and hedge funds own 0.62% of the company’s stock.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.